Trade Report: Today: Cryder Capital Partners LLP Boosts Stake in Thermo Fisher Scientific Inc. (TMO)

Today: Cryder Capital Partners LLP Boosts Stake in Thermo Fisher Scientific Inc. (TMO)

Cryder Capital Partners LLP raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.8% during the third quarter, Holdings Channel reports. The firm owned 164,704 shares of the company’s stock after buying an additional 39,780 shares during the period. Thermo Fisher Scientific accounts for about 15.4% of Cryder Capital Partners LLP’s holdings, making the stock its largest position. Cryder Capital Partners LLP’s holdings in Thermo Fisher Scientific were worth $26,198,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. British Columbia Investment Management Corp raised its position in Thermo Fisher Scientific by 3.3% in the second quarter. British Columbia Investment Management Corp now owns 263,934 shares of the company’s stock worth $38,999,000 after buying an additional 8,525 shares during the period. CHURCHILL MANAGEMENT Corp raised its position in Thermo Fisher Scientific by 228.7% in the second quarter. CHURCHILL MANAGEMENT Corp now owns 30,496 shares of the company’s stock worth $4,506,000 after buying an additional 21,218 shares during the period. Washington Trust Bank raised its position in Thermo Fisher Scientific by 68.8% in the second quarter. Washington Trust Bank now owns 2,211 shares of the company’s stock worth $327,000 after buying an additional 901 shares during the period. NEXT Financial Group Inc raised its position in Thermo Fisher Scientific by 2.2% in the second quarter. NEXT Financial Group Inc now owns 3,515 shares of the company’s stock worth $519,000 after buying an additional 75 shares during the period. Finally, Cohen Lawrence B raised its position in Thermo Fisher Scientific by 39.1% in the second quarter. Cohen Lawrence B now owns 14,040 shares of the company’s stock worth $2,075,000 after buying an additional 3,945 shares during the period. Hedge funds and other institutional investors own 86.28% of the company’s stock.

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO) traded down 2.9945% on Monday, reaching $139.8625. 2,277,214 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $149.80 and a 200 day moving average price of $151.94. The firm has a market cap of $55.25 billion, a PE ratio of 27.9557 and a beta of 1.24. Thermo Fisher Scientific Inc. has a one year low of $119.75 and a one year high of $160.68.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, October 27th. The company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.97 by $0.06. The business had revenue of $4.49 billion for the quarter, compared to analysts’ expectations of $4.39 billion. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period last year, the firm posted $1.80 earnings per share. Analysts expect that Thermo Fisher Scientific Inc. will post $8.25 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 16th. Shareholders of record on Thursday, December 15th will be given a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $0.60 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific’s payout ratio is 12.00%.

A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $178.00 price target on the stock in a research report on Monday, August 1st. Bank of America Corp. set a $180.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Friday, October 7th. Jefferies Group reiterated a “hold” rating on shares of Thermo Fisher Scientific in a research report on Thursday, August 4th. JPMorgan Chase & Co. began coverage on shares of Thermo Fisher Scientific in a research report on Thursday, September 22nd. They set an “overweight” rating and a $180.00 target price on the stock. Finally, Leerink Swann began coverage on shares of Thermo Fisher Scientific in a research report on Thursday, November 10th. They set an “outperform” rating and a $175.00 target price on the stock. Two research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $164.37.

In other news, CEO Marc N. Casper sold 30,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $151.17, for a total transaction of $4,535,100.00. Following the transaction, the chief executive officer now directly owns 308,647 shares of the company’s stock, valued at approximately $46,658,166.99. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 28,797 shares of Thermo Fisher Scientific stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $151.01, for a total value of $4,348,634.97. Following the transaction, the chief executive officer now directly owns 307,444 shares in the company, valued at $46,427,118.44. The disclosure for this sale can be found here. Insiders own 0.52% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Related posts

Leave a Comment